Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-masked randomized Phase 2 study of VEGF Trap-Eye in diabetic macular edema
2008-008200-40Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aflibercept in diabetic macular edema (DME), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Change in best-corrected ETDRS visual acuity (BCVA) from baseline to Week 24. Started Apr 2009; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2008-008200-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008200-40.